By Josh White
Date: Friday 29 May 2026
(Sharecast News) - CelLBxHealth said on Friday that it had entered into a master services agreement with AstraZeneca, establishing the company as a qualified service provider to the global pharmaceutical group.
| CelLBxHealth warns of lower-than-expected 2025 r... | 16-Jan-2026 | ShareCast |
| Holding(s) in Company | 23-Dec-2025 | ShareCast |
| PDMR Dealing and ESOT Share Purchase | 19-Dec-2025 | ShareCast |
| Angle founder and CEO steps down after sharehold... | 12-Sep-2025 | ShareCast |
| Shares in Angle tumble on gloomy outlook | 09-Sep-2025 | ShareCast |
| Master Services Agreement with Swiss biotech co | 21-Oct-2026 | 07:00 | RNS |
| Q3 Trading Update and FY 2026 Outlook | 21-Oct-2026 | 07:00 | RNS |
| New Statement of Work with US-Based Pharma Company | 14-Oct-2026 | 07:00 | RNS |
| Parsortix CTCs used for Brain Cancer detection | 11-Aug-2026 | 07:00 | RNS |
| Parsortix CTCs used for ADC target assessment | 03-Aug-2026 | 07:00 | RNS |
| New Angle for Braveheart | 26-Jan-2009 | The Scotsman |
| Market report: Monday latest | 07-Apr-2008 | Daily Mail |
| T&T float sinks amid turmoil | 07-Feb-2008 | Times |
| Carphone buzz may just be empty static | 01-Feb-2008 | Guardian |
| Greene King looks to life after cigarette ban | 02-Jul-2007 | The Independent |
| The Week Ahead: BSkyB boosted by 200,000 new sub... | 29-Jan-2007 | The Independent |
No recent information was found.
| Currency | UK Pounds |
| Share Price | 0.59p |
| Change Today | -0.038p |
| % Change | -6.00 % |
| 52 Week High | 2.65 |
| 52 Week Low | 0.57 |
| Volume | 465,710 |
| Shares Issued | 1,139.40m |
| Market Cap | £6.69m |
| Beta | 0.02 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 08:32 | 243,664 @ 0.57p |
| 08:09 | 222,046 @ 0.57p |
You are here: research